The Kidney Drug That Wasn't Supposed to Get Approved

For a disease with zero approved therapies and a 60% non-response rate to existing off-label treatments, those numbers were hard to ignore.

How Travere Talked the FDA Into It

The regulatory journey reads like an obstacle course. Travere first reported positive interim results in February 2021. Topline data arrived in May 2023, but the FDA wasn't convinced, issuing a Complete Response Letter (essentially a formal rejection) after determining the evidence was insufficient.

Most companies would've shelved the program. Travere went back to work.

They re-engaged with regulators, submitted additional analyses, and filed a supplemental application. An FDA advisory committee weighed in during 2025. The original decision date of January 13, 2026, got pushed back after the agency issued a major amendment extending its review. Three months of nail-biting later, the approval finally came through on April 13.

The persistence paid off because nephrologists were practically begging for something, anything, to prescribe. When your disease has no approved therapy and doctors report failure rates above 60%, even a drug that missed its primary endpoint but crushed its secondary ones starts looking pretty compelling.

Two Targets Are Better Than One

What makes Filspari genuinely novel is its mechanism. Most kidney-protective drugs block a single pathway: the renin-angiotensin system (the same system that blood pressure meds target). Filspari blocks two pathways simultaneously. It's a dual endothelin and angiotensin receptor antagonist, or DEARA, if you enjoy acronyms.

Think of kidney damage like a flood caused by two broken pipes. Traditional drugs (ARBs like irbesartan) fix one pipe. Filspari fixes both. One receptor it blocks, called endothelin type A, drives inflammation and scarring in kidney cells. The other, angiotensin II type 1, drives similar damage through a parallel route. Crucially, these two systems amplify each other; blocking both interrupts a vicious cycle that single-target drugs can't fully address.

The result: better proteinuria reduction without immunosuppression, which matters because immune-suppressing drugs carry their own serious risks.

Wall Street Smells a Blockbuster

Analysts are salivating. Filspari was already on the market for IgA nephropathy (another kidney disease), so Travere has sales infrastructure in place. The FSGS approval expands the eligible U.S. patient population to over 100,000 across both conditions.

Guggenheim bumped its price target to $54 with a Buy rating, estimating roughly 30,000 addressable FSGS patients. H.C. Wainwright reiterated Buy at $47. The most bullish forecasts see $1.5 billion in revenue and $577 million in earnings by decade's end.

Travere's stock has already surged substantially over the past year, pricing in much of the optimism. But the real question is execution: how quickly can they ramp FSGS prescriptions on top of existing IgA sales?

The Bigger Picture

Filspari's approval is more than a commercial milestone. It validates a principle that the biotech industry sometimes forgets: regulatory paths aren't always linear, and a missed primary endpoint doesn't have to be a death sentence.

For the thousands of FSGS patients who've been managing a progressive, kidney-destroying disease with borrowed tools, the math is simple. Something approved beats nothing approved. Every time.

Travere bet on persistence, creative regulatory strategy, and the strength of secondary data. The FDA, to its credit, listened. And 40,000 Americans finally have an option that didn't exist before.

Not bad for a drug that "failed" its trial.

UCB Just Bet $1.15 Billion That Brain Cells Can Cure Seizures

UCB is paying up to $1.15 billion for Neurona Therapeutics and its brain cell therapy that cut seizures by 92% in early trials. It's one of the boldest bets yet that cell therapy can work far beyond cancer.